Objective The purpose of this study was to investigate gouty arthritis in Japanese patients with end-stage renal disease (ESRD).
Introduction
Hyperuricemia and renal diseases are closely related. Chronic hyperuricemia leads to gouty kidney and nephrolithiasis. However, about 70% of uric acid, which is a final metabolite of purine bases, is excreted from the kidney; therefore, the deterioration of renal function causes hyperuricemia. Recent reports show that hyperuricemia plays a role in the initiation and progression of renal diseases in rodent models (1) (2) (3) (4) and that hyperuricemia indicates a poor renal prognosis in patients with IgA nephropathy (5) . These findings suggest that hyperuricemia can directly cause both gouty kidney and other renal diseases.
The prevalence of gouty arthritis is 10% to 20% in patients with hyperuricemia in the general population (6, 7) and shows the racial differences (8) . In Western patients with end-stage renal disease (ESRD) and high serum levels of uric acid, the incidence of gouty arthritis is low (9) ; however the incidence in Japanese patients is unclear. The purpose of this study was to clarify the incidence of gouty arthritis in Japanese patients with ESRD before and after the start of dialysis.
Patients and Methods

Patients
A total of 493 Japanese patients undergoing maintenance dialysis were investigated. These patients were 324 males and 169 females, of whom 413 were undergoing hemodialysis (HD) and 80 were undergoing continuous ambulatory peritoneal dialysis (CAPD). Their mean age was 59.9± 12.7 years (range, 15-93 years). The original renal diseases were chronic glomerulonephritis in 198 patients (40.2%), diabetic nephropathy in 138 patients (28.0%), nephrosclerosis in 43 patients (8.7%), polycystic kidney disease in 18 patients (3.7%), gouty kidney in 3 patients (0.6%), and unknown in 98 patients (18.9%). The rates of these diseases were similar to those in the general Japanese population undergoing maintenance dialysis (10) .
Gouty arthritis was investigated in patients with ESRD undergoing maintenance dialysis. We investigated gouty arthritis on the basis of: 1) the frequency of gouty arthritis in all patients, 2) the annual number of gouty attacks in patients with gouty arthritis before and after the start of dialysis. Laboratory data were obtained at the time of maintenance dialysis. Gouty arthritis was investigated with questionnaires plus patient interviews and reviews of medical records. Informed consent was obtained from all patients. In this study, gouty arthritis was diagnosed only when the criteria of the American Rheumatism Association was met (11) .
Statistical Analysis
The Chi-square test was used to analyze the relationship between gouty arthritis and various clinical variables. Differences between 2 groups were assessed with the MannWhitney U test and those among multiple groups were assessed with Scheffe's F test and analysis of variance. All analyses were performed with the "StatView for Windows version 5.0" software program. All data are shown as mean ± SD. Differences were considered significant when p<0.05.
Results
The patient profiles are shown in (Table 1) . Although the serum levels of creatinine and uric acid and the body mass index at the time of investigation were significantly higher in male patients than in female patients (p<0.0001, p=0.0218, and p<0.0001, respectively), there was no difference in the duration of dialysis. In addition, the clinical data were data obtained before dialysis at the beginning of the week for HD patients and were ambulant data for CAPD patients.
The frequency of gouty arthritis before and after the start of dialysis is shown in (Fig. 1 ). Greater than 2 years before the start of dialysis, the frequency of gouty arthritis was 4.1% for female patients and 15.4% for male patients. The frequency was 0.6% for female patients and 7.7% for male patients less than 2 years before the start of dialysis. After the start of dialysis, the frequency of gouty arthritis was 3.4% for the first 2 years and 1.2% thereafter in male patients, no cases of gouty arthritis occurred at the start of dialysis in female patients.
The number of gouty attacks per year before and after the start of dialysis in patients with ESRD and gouty arthritis is shown in (Fig. 2) . Greater than 2 years before the start of dialysis, the number of gouty attacks was 2.0±4.2 per year. The number of attacks was 1.9±6.6 per year less than 2 years before the start of dialysis. In contrast, the number of attacks decreased significantly after the start of dialysis to 0.2±0. The clinical variables associated with gouty arthritis were examined. In this analysis, the association between various clinical variables and gouty arthritis (the presence or absence of at least one gouty attack) was examined with the chisquare test. As shown in (Table 2) , gouty arthritis was not related to diuretic usage, alcohol consumption, or method of dialysis. In contrast, gouty arthritis was significantly more frequent in allopurinol users (p=0.0002), patients without diabetic nephropathy (p=0.0006), male patients (p=0.0006), and in patients with serum levels of creatinine > = 8.5 mg/dl (p= 0.0115).
Discussion
Although the frequency of gouty arthritis in patients with ESRD was similar to that in patients with hyperuricemia in the general population (6, 7) and tended to decrease before the start of dialysis, the frequency of gouty arthritis and the annual number of gouty attacks decreased markedly after the start of dialysis. Schreiner et al have reported that reduced secretion of proinflammatory cytokines stimulated by monosodium urate in chronic renal failure may be a factor preventing the manifestations of acute gout in many patients with ESRD despite the often severe hyperuricemia (12) . However, because there was no significant difference in the ability of monocytes to produce monosodium uratestimulated cytokines between patients receiving and those not receiving dialysis in their report, this reduced cytokine production ability in ESRD cannot explain the marked decrease in the frequency of gouty arthritis after the start of dialysis. Therefore, some factor promoting gouty arthritis might be removed by dialysis. Another possible reason for the marked reduction in gouty arthritis after the start of dialysis is that the body's pool of uric acid might be decreased by dialysis.
Ifudu et al have reported that the frequency of gouty arthritis in Western patients (white, black, and Hispanic patients) with ESRD before the start of dialysis was 6.5% (13 of 201 patients), and that no new cases of gouty arthritis occurred after the start of dialysis (9) . In the present study, the frequency of gouty arthritis before the start of dialysis was 14.0% (69 of 493 patients), and that after the start of dialysis was 2.8% (14 of 493 patients). Interestingly, the gouty arthritis developed after the start of dialysis in 1.4% (7 of 493 patients). This development of gouty arthritis after the start of dialysis might be due to the rapid decrease in serum levels of uric acid. Therefore, although our data in Japanese patients support the findings of Ifudu et al (9) , the frequency of gouty arthritis after the start of dialysis was extremely low but not zero.
Gouty arthritis was more frequently seen in patients with ESRD receiving uric acid-lowering medicine (allopurinol) than in patients not receiving this medicine (Table 2) . A review of medical records showed that patients with gouty arthritis received allopurinol more frequently than did patients without gouty arthritis. Examination of the renal disease leading to ESRD showed that the frequency of gouty arthritis was lower in patients with diabetic nephropathy than in patients without diabetic nephropathy. This observation supports the finding of Gomi et al that gouty arthritis is a rare complication of diabetes mellitus (13) .
In the general population almost all cases of gouty arthritis occur in male patients. In Japan, 99% of patients with gouty arthritis are male (14) . In the present study of patients with ESRD, although the frequency of gouty arthritis was 21.9% (71 of 324 patients) in male patients, it was 4.7% (8 of 169 patients) in female patients, which was higher than that in female patients in the Japanese general population. We believe this high rate is due to the high frequency of hyperuricemia in female patients with ESRD. The serum level of uric acid at the time of investigation was 7.6±1.5 mg/dl in female patients and 7.9±1.6 mg/dl in male patients (p=0.0218) (Table 1) . Allopurinol, a xanthine oxidase inhibitor, is commonly used for hyperuricemia control in patients with renal insufficiency. In patients with renal insufficiency, the serum level of oxipurinol, an active metabolite of allopurinol, rises and leads to various adverse effects (15) . Our results suggest that allopurinol is rarely needed to control gouty arthritis, at least after the start of dialysis in patients with ESRD, because the frequency of the gouty arthritis decreases markedly. However, whether hyperuricemia, a risk factor for cardiovascular disease (16) (17) (18) , should be treated in patients receiving dialysis has not been determined.
In summary, we investigated gouty arthritis in Japanese patients receiving maintenance dialysis. We found that although the frequency of gouty arthritis was similar to that of patients with hyperuricemia in the general population and decreased slightly before the start of dialysis, the frequency decreased markedly after the start of dialysis.
